Volcker's regulatory suggestions rile money market execs - Adviser Investments
Market News / All Articles /

Volcker’s regulatory suggestions rile money market execs

Featuring: Jim Lowell August 25, 2009
Read on InvestmentNews open_in_new

Recent Articles

View All Articles

Vanguard may be shorting much vaunted ‘owners’ of its low-cost index funds as it shifts to Wall Street-style exec-comp tactics to thwart competitors and chase high-net-worth investors

Featuring: Daniel Wiener May 16, 2022
Read on RIA Biz open_in_new

Fidelity’s strategy to own the financial advice business by owning ‘a crazy lot of people’ is heading for 28,000 hires in two years

Featuring: Jim Lowell May 13, 2022
Read on RIA Biz open_in_new

Orion Acquiring CRM Provider Redtail

Featuring: Alec Rosen April 20, 2022
Read on WealthManagement.com open_in_new

Dan Wiener’s Adviser Investments to Acquire Polaris as It Pursues National Ambitions

Featuring: Daniel Wiener April 13, 2022
Read on Barron’s open_in_new

Vanguard, American Express Team Up for New Service

Featuring: Jeffrey DeMaso April 13, 2022
Read on Ignites open_in_new

With McKinsey helping to up its ‘efficiency,’ Vanguard Group does eye-opening client acquisition deal with American Express that layers a big fee onto financial planning offering that the two firms roughly split

Featuring: Daniel Wiener April 13, 2022
Read on RIA Biz open_in_new

Adviser Investments buys $2bn California RIA

Featuring: Daniel Wiener April 12, 2022
Read on Citywire open_in_new

Vanguard ETF Product Chief to Lead Private Equity

Featuring: Daniel Wiener March 28, 2022
Read on Ignites open_in_new

Edward ‘Ned’ Johnson, Former Fidelity CEO and Fund Pioneer, Dies

Featuring: Jim Lowell March 25, 2022
Read on Barron’s open_in_new

Suit against Vanguard focuses on big tax bills for target-date funds

Featuring: Daniel Wiener March 16, 2022
Read on InvestmentNews open_in_new

Vanguard Hikes Bonus at Fastest Rate in 35 Years

Featuring: Daniel Wiener March 10, 2022
Read on Ignites open_in_new

Vanguard stopped buying Russian stocks. AmerisourceBergen said it’s still supporting patients in drug trials there

Featuring: Jeffrey DeMaso March 9, 2022
Read on The Philadelphia Inquirer open_in_new

Adviser Investments' logo is a registered trademark of Adviser Investments, LLC.